Javier Salvador

Prof. Javier Salvador

Faculty of Medicine - University of Navarra, Pamplona, Spain
+1
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2022 in Obesity Facts
Verified
Journal Article
Open access
PDF file
Lorenzo Maria DoniniLorenzo Maria Donini
Lorenzo Maria Donini
LBLuca Busetto
Luca Busetto
SBStephan C. Bischoff
Stephan C. Bischoff
TCTommy Cederholm
Tommy Cederholm
MBMaría D. Ballesteros-Pomar
María D. Ballesteros-Pomar
RBRocco Barazzoni
Rocco Barazzoni
Introduction: Loss of skeletal muscle mass and function (sarcopenia) is common in individuals with obesity due to metabolic changes associated with a sedentary lifestyle, adipose tissue derangements, comorbidities (acute and chronic diseases) and during the ageing process. Co-existence of excess adiposity and low muscle mass/function is referred to as sarcopenic obesity (SO), a condition increasingly recognized for its clinical and functional features that negatively influence important patient-centred outcomes. Effective prevention and treatment strategies for SO are urgently needed, but efforts are hampered by the lack of a universally established SO definition and diagnostic criteria. Resulting inconsistencies in the literature also negatively affect the ability to define prevalence as well as clinical relevance of SO for negative health outcomes. Aims and Methods: The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) launched an initiative to reach expert consensus on a definition and diagnostic criteria for SO. The jointly appointed international expert panel proposes that SO is defined as the co-existence of excess adiposity and low muscle mass/function. The diagnosis of SO should be considered in at-risk individuals who screen positive for a co-occurring elevated body mass index or waist circumference, and markers of low skeletal muscle mass and function (risk factors, clinical symptoms, or validated questionnaires). Diagnostic procedures should initially include assessment of skeletal muscle function, followed by assessment of body composition where presence of excess adiposity and low skeletal muscle mass or related body compartments confirm the diagnosis of SO. Individuals with SO should be further stratified into stage I in the absence of clinical complications or stage II if cases are associated with complications linked to altered body composition or skeletal muscle dysfunction. Conclusions: ESPEN and EASO, as well as the expert international panel, advocate that the proposed SO definition and diagnostic criteria be implemented into routine clinical practice. The panel also encourages prospective studies in addition to secondary analysis of existing data sets, to study the predictive value, treatment efficacy and clinical impact of this SO definition.

22 February 2022 in Clinical Nutrition
Verified
Journal Article
Closed access
Lorenzo Maria DoniniLorenzo Maria Donini
Lorenzo Maria Donini
Luca BusettoLuca Busetto
Luca Busetto
SBStephan C. Bischoff
Stephan C. Bischoff
TCTommy Cederholm
Tommy Cederholm
MBMaria D. Ballesteros-Pomar
Maria D. Ballesteros-Pomar
RBRocco Barazzoni
Rocco Barazzoni

22 February 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
GFGema Frühbeck
Gema Frühbeck
Victoria CatalánVictoria Catalán
Victoria Catalán
ARAmaia Rodríguez
Amaia Rodríguez
BRBeatriz Ramírez
Beatriz Ramírez
SBSara Becerril
Sara Becerril
Javier Gomez-AmbrosiJavier Gomez-Ambrosi
Javier Gomez-Ambrosi
Obesity favors the development of cardiometabolic alterations such as type 2 diabetes (T2D) and the metabolic syndrome (MS). Obesity and the MS are distinguished by an increase in circulating leptin concentrations, in parallel to a drop in the levels of adiponectin. Consequently, the Adpn/Lep ratio has been suggested as a maker of dysfunctional adipose tissue. We aimed to investigate in humans (n = 292) the reliability of the Adpn/Lep ratio as a biomarker of adipose tissue dysfunction. We considered that an Adpn/Lep ratio of ≥1.0 can be considered normal, a ratio of ≥0.5 <1.0 suggests moderate-medium increased risk, and a ratio of <0.5 indicates a severe increase in cardiometabolic risk. Using these cut-offs, 5%, 54% and 48% of the lean, normoglycemic and without-MS subjects, respectively, fall within the group with an Adpn/Lep ratio below 0.5; while 89%, 86% and 90% of the obese, with T2D and with MS patients fall within the same group (p < 0.001). A significant negative correlation (r = −0.21, p = 0.005) between the Adpn/Lep ratio and serum amyloid A (SAA) concentrations, a marker of adipose tissue dysfunction, was found. We concluded that the Adpn/Lep ratio is a good indicator of a dysfunctional adipose tissue that may be a useful estimator of obesity- and MS-associated cardiometabolic risk, allowing the identification of a higher number of subjects at risk.

19 August 2019 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
CFCintia Folgueira
Cintia Folgueira
DBDaniel Beiroa
Daniel Beiroa
BPBegoña Porteiro
Begoña Porteiro
MDManon Duquenne
Manon Duquenne
EPEmma Puighermanal
Emma Puighermanal
RNRuben Nogueiras
Ruben Nogueiras

14 June 2017 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
BCBorja Corcóstegui
Borja Corcóstegui
SDSantiago Durán
Santiago Durán
MGMaría Olga González-Albarrán
María Olga González-Albarrán
CHCristina Hernández
Cristina Hernández
JRJosé María Ruiz-Moreno
José María Ruiz-Moreno
Rafael SimóRafael Simó
Rafael Simó
A group of members of the Spanish Retina and Vitreous Society (SERV) and of the Working Group of Ocular Health of the Spanish Society of Diabetes (SED) updated knowledge regarding the diagnosis and treatment of diabetic retinopathy (DR) based on recent evidence reported in the literature. A synthesis of this consensus forms the basis of the present review, which is intended to inform clinicians on current advances in the field of DR and their clinical applicability to patients with this disease. Aspects presented in this article include screening procedures of DR, new technologies in the early diagnosis of DR, control of risk factors in the different stages of the disease, indications of panretinal laser photocoagulation, efficacy of intravitreal antiangiogenic agents and steroids, and surgical options for treating DR-related complications. Practical information regarding periodicity of screening procedures in patients with type 1 and type 2 diabetes, ophthalmological controls according to the stage of retinopathy and complications, and criteria and degree of urgency for referral of a DR patient to the ophthalmologist are also presented.

3 September 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
XUXabier Unamuno
Xabier Unamuno
MIMaitane Izaguirre
Maitane Izaguirre
Javier Gomez-AmbrosiJavier Gomez-Ambrosi
Javier Gomez-Ambrosi
ARAmaia Rodríguez
Amaia Rodríguez
BRBeatriz Ramírez
Beatriz Ramírez
Victoria CatalánVictoria Catalán
Victoria Catalán
Bariatric surgery remains the most effective option for achieving important and sustained weight loss. We explored the effects of Roux-en-Y gastric bypass (RYGB) on the circulating levels of adiponectin, leptin, and the adiponectin/leptin (Adpn/Lep) ratio in patients with obesity and type 2 diabetes (T2D). Twenty-five T2D volunteers undergoing RYGB were included in the study, and further subclassified as patients that responded or not to RYBG, regarding remission of T2D. Anthropometric and biochemical variables were evaluated before and after RYGB. Obese patients with T2D exhibited an increase (p < 0.0001) in the Adpn/Lep ratio after RYGB. Changes in the Adpn/Lep ratio correlated better with changes in anthropometric data (p < 0.001) than with the variations of adiponectin or leptin alone. Multiple regression analysis revealed that the change in the Adpn/Lep ratio in patients with T2D was an independent predictor of the changes in body mass index (p < 0.001) and body fat percentage (p = 0.022). However, the Adpn/Lep ratio did not differ between individuals with or without T2D remission after RYGB. In summary, the current study demonstrated that after weight and body fat loss following RYGB, the Adpn/Lep ratio increased in patients with obesity and T2D.